A 61-year-old man with angioimmunoblastic lymphoma in first complete remission underwent autologous peripheral blood stem cell transplantation. At 1 month post transplant, asymptomatic large granular lymphocytosis developed. The surface marker profile of the cells was CD3 þ CD8 þ CD56ÀCD57 þ . The disease course was chronic and indolent. The patient remains in complete remission from angioimmunoblastic lymphoma more than 6 months post transplant with persistent large granular lymphocytosis (lymphocyte count, 5-15 Â 10 9 /l). Although post transplantation T-cell lymphoproliferative disorders have mostly occurred in allogeneic transplantation recipients and presented as aggressive lymphomas/leukemias, we suggest that chronic indolent T-cell large granular lymphocytic leukemia can occur after autologous stem cell transplantation.
post transplantation lymphoproliferative disorders; autologous peripheral blood stem cell transplantation T-cell large granular lymphocytic (T-LGL) leukemia is a lymphoproliferative disease derived from post-thymic immunocompetent T lymphocytes. 1 Large granular cell morphology, CD3 þ CD56ÀCD57 þ immunophenotype and the clonal rearrangement of T-cell receptor genes characterize T-LGL leukemia, which presents clinically with a chronic indolent disease course, complicated by frequent infections secondary to neutropenia.
Post transplantation lymphoproliferative disorders (PTLD) are a well-recognized complication of solid organ and allogeneic bone marrow transplantation, and accumulating data have suggested that aggressive immunosuppression is closely associated with an increased risk of PTLD. 2, 3 The majority of PTLD are of B-cell origin and are associated with active infection with Epstein-Barr virus (EBV). T-cell PTLD are much less common but, similar to B-cell PTLD, they mostly present as aggressive lymphomas following a rapidly fatal course. 4, 5 EBV is infrequently involved in the pathogenesis. Autologous stem cell transplantation (ASCT) is another transplantation procedure. In spite of the profound myelosuppression associated with autografting, this procedure is inherently less immunosuppressive than allogeneic bone marrow transplantation and we were able to find less than 20 cases in the English literature describing PTLD following ASCT. [6] [7] [8] Here, we report the first case of chronic T-LGL leukemia following ASCT for angioimmunoblastic lymphoma.
Case report
A 61-year-old man was admitted to our hospital in April 1997 because of fever, skin rash, edema, generalized lymphadenopathy and hemolysis. On physical examination, there was a maculo-papular rash on the trunk and extremities, and superficial lymphadenopathy was found in various regions including the neck, axilla and groin. A left pleural effusion and moderate splenomegaly (20 mm on the left midclavicular line) were also noted. The hemoglobin (Hb) was 8.1 g/dl, white blood cell count (WBC) 9.1 Â 10 9 /l with 72% neutrophils, 18% lymphocytes, 9% monocytes and 1% eosinophils, and platelet count (PLT) 241 Â 10 9 /l. Serum immunoglobulin levels were elevated with no monoclonal band. The serum haptoglobin level was under the detection limit; the direct antiglobulin test was positive. Biopsy of an inguinal lymph node showed the histologic features of angioimmunoblastic T-cell lymphoma by the World Health Organization Classification. Immunohistochemistry revealed that most infiltrating T cells had a helper/inducer phenotype CD3 þ CD4 þ CD8À. The patient entered complete remission with four cycles of standard CHOP chemotherapy, and underwent stem cell mobilization with high-dose etoposide (500 mg/m 2 for 3 days) plus G-CSF. He was then treated with two additional cycles of CHOP. At 6 months after the initial diagnosis, he received myeloablative therapy with our standard highdose regimen for lymphoma consisting of ranimustine, cyclophosphamide, etoposide and carboplatin. He received 10 Â 10 6 CD34 þ cells/kg and his platelets engrafted on day þ 15 and neutrophils on day þ 11. His early post-ASCT course was complicated by grade II mucositis and culturenegative febrile neutropenia.
After 1 month, a pronounced granular lymphocytosis developed without any clinical manifestations (Figure 1 Table 1 ). The karyotype of peripheral blood mononuclear cells including LGLs was normal. Clonal rearrangement of the T-cell receptor-g chain gene was detected from DNA of the cells (Figure 2 ). The pattern of the rearranged fragments in LGLs was different from that in the pretransplant lymphoma specimen, suggesting that the angioimmunoblastic lymphoma and the T-LGL leukemia were clonally unrelated. He was seronegative for both human T-cell lymphotropic virus type I and human immunodeficiency virus. The patient was repeatedly negative for blood cytomegalovirus (CMV) antigenemia. EBV DNA was not detected in the serum by polymerase chain reaction. Tetramer assay using fluorescent-labelled tetramers of HLA-A24 complexed with virus peptide epitopes did not detect EBVor CMV-specific T-cell populations. The patient remains in complete remission from angioimmunoblastic lymphoma more than 6 months post transplant, with a persistent large granular lymphocytosis (lymphocyte count, 5-15 Â 10 9 /l). Neither cytopenias nor lymphadenopathy have developed. LGL: large granular lymphocyte count. Table 1 Immunophenotyping of large granular lymphocytes 
% Positive cells % Positive cells T/NK-Ags B-Ags
CD1b o5 C D 1 0 o5 CD2 81 CD19 o5 CD3 78 CD20 o5 CD4 9 CD5 80 My-Ags CD7 68 CD13 o5 CD8 73 CD14 o5 CD16 o5 CD56 7 Other-Ags CD57 21 TdT o5 CD94 54 TIA-1 490 CD158A 7 Granzyme B 45 CD158B 8 CD161 7
Discussion
This case is of clinical interest since both chronic and indolent T-cell lymphoproliferation occurred after ASCT. T-LGL leukemia was distinguished from conditions associated with a reactive polyclonal increase in granular lymphocytes based on the clinical course, aberrant coexpression of the natural killer cell-associated antigen CD57 as well as expression of cytolytic antigens TIA-1 and granzyme B, and demonstration of T-cell clonality. 1, 9 There have been four cases of post transplant T-LGL leukemia in the literature, 10, 11 which occurred in three renal transplant recipients and one liver transplant recipient. In those cases, the clinical courses were indolent and the presence of T-LGL leukemia did not affect prognosis. It is therefore possible that T-cell PTLD with typical features of de novo T-LGL leukemia can run a benign chronic course.
The time interval from the transplant to the appearance of post transplant T-LGL leukemia in the cases previously described varied from 3 months to 11 years, longer than B-cell PTLD. 3, 10, 11 In contrast, in the present case, the LGLs were among the first cells to recover after autologous transplantation. The lymphoproliferation was not related to underlying angioimmunoblastic lymphoma. We speculate that the development of T-LGL leukemia in the early post transplant period was associated with autografting. Unfortunately, at present, a sequence of events that may precede the development of T-LGL leumemia has not been identified.
